Debbie Rigby takes a look at the latest research relevant to community pharmacy
Non-hormonal drugs are considered an option for treatment of vasomotor symptoms for women with contraindications to hormone therapy. A meta-analysis of 39 studies has concluded that SSRIs/SNRIs, gabapentin, and clonidine have a rapid onset, which could reach the maximum effect immediately. However, the onset of soy isoflavones was very slow, and a duration of 16.6 weeks was needed to surpass the efficacy of paroxetine. The efficacy of non-hormonal drugs was significantly lower than that of oestrogen.
European Journal of Clinical Pharmacology 2016;72(9):1051-8.
This review of treatment for osteoporosis highlights the need for fracture risk assessment in selecting patients who require specific anti-osteoporosis therapy. The actions of antiresorptive drugs, bisphosphonates, oestrogen, selective oestrogen receptor-modulating drugs, strontium ranelate, and the human monoclonal antibody denosumab and the anabolic agent, teriparatide are summarised. The review concludes that the benefits of treatment far outweigh any risks associated with long term treatment.
Med J Aust 2016; 205 (4): 185-190.
A literature search has identified roles for community pharmacists in identification and management of COPD. These include primary prevention, early detection/case finding, management and ongoing support and review and follow-up. Areas requiring additional consideration include pharmacist training, increasing awareness of the pharmacist role, administration and reimbursement, and increasing physician—pharmacist collaboration. Pharmacists should play an important role in monitoring adherence and ongoing inhaler technique.
British Journal of Clinical Pharmacology 2016
Previous studies have suggested an association between frequent paracetamol use and asthma-related complications among children. However, this multicentre RCT of 300 children with mild persistent asthma aged between 12 and 59 months did not find a higher incidence of asthma exacerbations or worse asthma control with paracetamol compared with ibuprofen over a one-year period.
N Engl J Med 2016; 375:619-630.